Protocol: influence of budesonide and budesonide/formoterol on asthma control in smoking asthmatic adults.
BACKGROUND
A reduced response to inhaled corticosteroids (ICS) has been reported in smoking asthmatic patients but the effects of other medications remain to be evaluated in this population.


METHODS
We evaluated the effects of a combined therapy of budesonide 200 microg twice daily and formoterol 6 microg twice daily compared with budesonide 200 microg twice daily alone on asthma control questionnaire (ACQ), asthma quality of life questionnaire (AQLQ- Juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period. Seventeen smoking and 22 non-smoking patients not using inhaled corticosteroids with slightly uncontrolled mild asthma completed the study.


RESULTS
ACQ and AQLQ scores were similar in both groups at baseline and improved similarly after treatments. beta2-agonist use was higher in smokers, regardless of the treatment received (p=0.03), as it was on baseline (p=0.003). Smokers treated with budesonide/formoterol showed an increase in the number of asthma episodes (intercurrent asthma symptoms, p=0.016) while non-smoking subjects had a significant decrease in these episodes (p=0.009). No difference was found between smokers and non-smokers in regard to post-treatment airway inflammatory parameters.


CONCLUSIONS
No significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months. This should be further explored in larger groups of subjects.
Boulet
Louis-Philippe
LP
Centre de recherche de institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada.
Deschesnes
Francine
F
Chaboillez
Simone
S
Lemière
Catherine
C
Am J Respir Crit Care Med. 2007 Apr 15;175(8):749-50
17484086
Chest. 2001 Dec;120(6):1917-22
11742922
Am J Public Health. 2002 Jun;92(6):1002-6
12036796
Eur Respir J. 1999 Oct;14(4):902-7
10573240
Thorax. 2002 Mar;57(3):226-30
11867826
Chest. 2006 Mar;129(3):661-8
16537865
Clin Exp Allergy. 2003 Nov;33(11):1471-5
14616855
Can Respir J. 2004 May-Jun;11 Suppl A:9A-18A
15254605
Monaldi Arch Chest Dis. 2001 Aug;56(4):349-53
11770219
Am Rev Respir Dis. 1987 Jul;136(1):225-44
3605835
Am Rev Respir Dis. 1987 Nov;136(5):1285-98
3674589
Am J Respir Crit Care Med. 1996 May;153(5):1519-29
8630596
Can Respir J. 2005 Mar;12(2):79-80
15785796
J Asthma. 1999 May;36(3):257-64
10350222
Eur Respir J. 2000 Mar;15(3):470-7
10759439
Am J Respir Crit Care Med. 1996 May;153(5):1481-8
8630590
Allergy. 2007 Feb;62(2):120-5
17298419
Am J Respir Crit Care Med. 2007 Apr 15;175(8):783-90
17204725
Eur Respir J. 1999 Jul;14(1):32-8
10489826
Am Rev Respir Dis. 1983 Jun;127(6):725-34
6859656
Treat Respir Med. 2006;5(6):467-81
17154674
N Engl J Med. 1998 Oct 22;339(17):1194-200
9780339
Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1392-7
11704584
Eur Respir J. 2004 Nov;24(5):822-33
15516679